Mitapivat is the first disease-modifying pharmacotherapy shown to have beneficial effects on iron overload in adult patients with PK deficiency through its multimodal action, including modulating the erythroferrone–hepcidin axis. This evidence concerns the gene HAMP and Tangier disease.